Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluoxetine 10 mg in Healthy Adults
NCT05532332Phase 1Completed
- Sponsor
- Future University in Egypt
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluoxetine in major depressive disorder (MDD) (2 arms), sponsored by Future University in Egypt. Primary endpoints: Maximum plasma concentration at 72 hours and Truncated area under the plasma concentration curve at 72 hours. Started Jan 2021; status: completed.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05532332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532332.